



PRESS RELEASE

Nobel Biocare Holding AG: First trading day in Zurich and Stockholm for new share

On Monday, June 24, 2002, the shares of Nobel Biocare Holding AG were introduced on the Zurich and Stockholm stock exchanges and trading started this morning.

This follows the successful share exchange offer from Nobel Biocare Holding AG to the shareholders of Nobel Biocare AB. The new shares are being quoted on the Main Board of the SWX Swiss Exchange and on the A-list, Most traded list, on the Stockholm Stock Exchange.

In a comment, Heliane Canepa, CEO of Nobel Biocare, says:

“The successful implementation of the new holding structure of Nobel Biocare will improve our strong position as the market leader in dental implants and prosthetics and our brand name even further. Through the dual listing the visibility of Nobel Biocare will increase in all markets and we welcome this opportunity also to attract new shareholders”.

Gothenburg, 24 June 2002

Nobel Biocare Holding AG

For further information:

Heliane Canepa, President & CEO, Nobel Biocare AB, tel. +46 31 81 88 00

Gunilla Ekholtz, Investor Relations Officer, Nobel Biocare AB, tel. +46 31 81 88 36

Nobel Biocare is an innovative, medical devices company, whose core business comprises dental implants and dental prosthetics. The company's product systems for dental implants, Brånemark System® and Replace™, are world leaders and have a global market share of around 38%.

The company's other product line, Procera®, is a unique, IT-based process for the industrial production of dental prosthetics. The system has been launched very successfully in more than 35 countries in North America, Europe, South East Asia and South America.

Nobel Biocare has around 1,300 employees and, in 2001 net sales totaled SEK 2 663 million. The company's headquarters are located in Gothenburg, Sweden, while production takes place in Sweden and the USA. Nobel Biocare has its own sales companies in 26 countries.

**Nobel Biocare AB, Box 5190, S-402 26 Göteborg, Sweden,
tel +46 31-81 88 00, fax +46 31-16 31 52.**

investor.relations@nobelbiocare.com

www.nobelbiocare.com